






1  
2 **Figure S1. Basic information of the 140 PCNSL patients**

3 The key demographic and clinical characteristics of PCNSL patients are summarized in the  
4 upper half of the figure, while the proportions of patients with these characteristics are  
5 presented in the lower half. Related to Figure 1.



7 **Figure S2. PCNSL mutational landscape and variation signature**

8 A: Variant classification, type, and single-nucleotide variation class for PCNSL patients (n =  
9 140).


10 B: Oncogene pathways in 140 PCNSL patients.

11 C: Arm-level copy number alterations in 140 PCNSL patients.

12 D: Contribution of mutational signatures in 140 PCNSL patients.

13 E: The most significant contributions to the PCNSL genome.

14 Related to Figure 1.





16 **Figure S3. Genetic variation events and tumor mutational burden (TMB) in the 140**  
17 **PCNSL samples**


18 A: Genetic variation events in 140 PCNSL samples and the TMB of PCNSL, ranking 2nd in  
19 the TCGA database.


20 B: Genetic variation events in the discovery cohort of PCNSL patients (n = 58) and the TMB  
21 of PCNSL patients, ranking 5th in the TCGA database.


22 C: Genetic variation events in the validation cohort of PCNSL patients (n = 82) and the TMB  
23 of PCNSL patients, ranking 1st in the TCGA database.


24 D: The mutually exclusive or co-occurrence relationships of these genes.

25 Related to Figure 1.










30 **Figure S4.** Kaplan–Meier estimates of overall survival associated with candidate cancer  
31 genes with mutation frequencies exceeding 10% and the NOTCH1, NOTCH2, and EZH2  
32 genes.

33 Related to Figure 1.



34

35

**Figure S5. Mutation Profiles and Signatures of the Discovery and Validation Cohorts**



36 A: Variant classification, type, and single-nucleotide variation (SNV) class in the discovery  
37 cohort of PCNSL patients (n = 58).

38 B: Variant classification, type, and single-nucleotide variation (SNV) class in the validation  
39 cohort of PCNSL patients (n = 82).


40 C: Number and frequency of recurrent mutations, along with a gene–sample matrix of  
41 recurrently mutated genes, ranked by mutation frequency in the discovery cohort of PCNSL  
42 patients (n = 58).

43 D: Number and frequency of recurrent mutations, along with a gene–sample matrix of  
44 recurrently mutated genes, ranked by mutation frequency in the validation cohort of PCNSL  
45 patients (n = 82).


46 E: GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).  
47 Genes affected by each focal event are annotated in the discovery cohort (n = 58). X-axis:  
48 plot of chromosomes; Y-axis: G score.

49 F: GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).  
50 Genes affected by each focal event are annotated in the validation cohort (n = 82). X-axis:  
51 plot of chromosomes; Y-axis: G score.

52 G: The most significant contributions to the PCNSL genome in the discovery cohort (n = 58).  
53 H: The most significant contributions to the PCNSL genome in the validation cohort (n = 82).  
54 Related to Figure 2.



56 **Figure S6. The prognostic value of published molecular subtypes for progression-**  
57 **free survival (PFS) and overall survival (OS) in our Chinese PCNSL cohort**  
58 A: Prognostic value of the DLBCL COO molecular subtype (GCB, non-GCB) for OS and  
59 PFS in our Chinese PCNSL cohort  
60 B: The prognostic value of DLBCL LymphPlex molecular subtypes (BN2, MCD, EZB, N1,  
61 TP53, and others) for OS and PFS in our Chinese PCNSL cohort  
62 C: The prognostic value of M.A. Shipp's team's DLBCL molecular subtypes (C0, C1, C2, C3,  
63 C4, and C5) for OS and PFS in our Chinese PCNSL cohort  
64 D: The prognostic value of L.M. Staudt's team's DLBCL molecular subtypes (BN2, EZB,  
65 MCD, N1, and others) for OS and PFS in our Chinese PCNSL cohort  
66 E: The prognostic value of L.M. Staudt's DLBCL molecular subtypes (A53, BN2, EZB, MCD,  
67 N1, ST2, and others) for OS and PFS in our Chinese PCNSL cohort.  
68 F: Prognostic value of A. Alentorn team's PCNSL molecular subtypes (CS1, CS2, CS3, and  
69 CS4) for OS and PFS in our Chinese PCNSL cohort  
70 Related to Figure 3.




71

72 **Figure S7. The prognostic value of the double-hit gene expression signature**  
 73 **subtypes for progression-free survival (PFS) and overall survival (OS) in our Chinese**  
 74 **PCNSL cohort**

75 A: The prognostic value of double-hit gene expression signature subtypes (double or triple  
 76 hit vs. others) for OS and PFS in our Chinese PCNSL discovery cohort (n = 58)

77 B: The prognostic value of double-hit gene expression signature subtypes (double or triple  
 78 hit vs. others) for OS and PFS in our Chinese PCNSL validation cohort (n = 82)

79 C: The prognostic value of double-hit gene expression signature subtypes (double or triple  
 80 hit vs. others) for OS and PFS in our Chinese PCNSL cohort (n = 140).



83 **Figure S8. Schematic of the typing strategies used to identify PCNSL molecular**  
84 **subtypes**

85 A: CoxNet survival analyses and least absolute shrinkage and selection operator (LASSO)  
86 regressions were employed to determine the importance score of each feature in the model,  
87 all of which were then ranked. This process was repeated 500 times, and all potential  
88 features were recorded. This is a demonstration of the aforementioned process.





89 B: Kaplan–Meier (K–M) analyses of the 6 identified features were conducted.

90 C: Venn diagram illustrating how these 6 features were randomly combined to form three  
91 types.

92 D: Seven candidate molecular subtype combinations were identified in the discovery cohort.

93 E: Seven candidate molecular subtype combinations were validated in the validation cohort.

94 Related to Figure 4.







96 **Figure S9. Mutation diagrams (Lollipop Figures) for the EP300, IRF4, BTG1, and**  
97 **MYD88 genes**



98 For each gene, all nonsynonymous mutations within the functional domains of the  
99 respective protein were visualized via maftools.

100 Related to Figure 4.



A



B



C











102 **Figure S10. Kaplan–Meier analyses of the EP300, IRF4, BTG1, and MYD88 genes and**  
103 **molecular subtypes**

104 A: Prognostic value of mutations in the EP300, IRF4, BTG1, and MYD88 genes for OS.

105 B: Prognostic value of mutations in the EP300, IRF4, BTG1, and MYD88 genes for  
106 progression-free survival (PFS).


107 C: Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS)  
108 among 140 PCNSL patients with each molecular subtype.

109 Related to Figure 4.




111 **Figure S11. Kaplan–Meier estimates of the impact of BTK inhibitor use on prognosis**  
112 A: The prognostic value of BTK inhibitor use for overall survival (OS) in all 140 PCNSL  
113 patients and patients with each molecular subtype.  
114 B: Prognostic value of BTK inhibitor use for progression-free survival (PFS) in all 140  
115 PCNSL patients and patients with each molecular subtype.  
116 Related to Figure 4.


**A**




**B**



**C**





**D**



118 **Figure S12. Mutation profiles and signatures across the three MSs**  
119 A. Variant classification, type, and single-nucleotide variation (SNV) class across the E3,  
120 BMI, and UC subtypes.  
121 B. GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).  
122 Genes affected by each focal event are annotated. X-axis: plot of chromosomes; Y-axis: G  
123 score.  
124 C. Contributions of mutational signatures across the E3, BMI, and UC subtypes.  
125 D. The most significant contributions to the PCNSL genome across the E3, BMI, and UC  
126 subtypes.  
127 Related to Figure 6.





128


129

130

131

**Figure S13.** Hematoxylin–eosin staining and immunohistochemistry (A) for CD2, CD5, CD10, CD19, CD20, CD79a, Ki-67, BCL2, BCL6, MUM1, C-Myc, and p53, and oncogene pathways (B) in samples from different PCNSL subtypes





134 **Figure S14. Mutational profiles of deep brain and shallow brain tumors in PCNSL**  
135 A: Difference in tumor sites in the discovery versus validation cohorts.  
136 B: Venn diagram of unique and shared mutations in deep brain and shallow brain tumors.  
137 C: The number and frequency of recurrent mutations, along with a gene-sample matrix of  
138 recurrently mutated genes in PCNSL patients between deep brain and shallow brain tumors,  
139 are presented. The relative abundance across the molecular subtypes is displayed on the  
140 right.  
141 D: Arm-level copy number alterations between deep brain and shallow brain tumors are  
142 displayed. The frequencies of amplifications and deletions were compared.  
143 E: The levels of mutant-allele tumor heterogeneity (MATH) were compared between deep  
144 brain and shallow brain tumors.  
145 F: The tumor mutational burden (TMB) was compared between deep brain and shallow  
146 brain tumors.  
147 G: The levels of microsatellite instability (MSI) were compared between deep brain and  
148 shallow brain tumors.  
149 H: Pathways affected by oncogenes in PCNSL patients between deep brain and shallow  
150 brain tumors.  
151 The chi-squared test and one-way ANOVA were used. \* $P < 0.05$ , <sup>ns</sup> $P > 0.05$   
152 Related to Figure 7.  
153